JPS5852225A - 脱髄疾患治療剤 - Google Patents
脱髄疾患治療剤Info
- Publication number
- JPS5852225A JPS5852225A JP56148725A JP14872581A JPS5852225A JP S5852225 A JPS5852225 A JP S5852225A JP 56148725 A JP56148725 A JP 56148725A JP 14872581 A JP14872581 A JP 14872581A JP S5852225 A JPS5852225 A JP S5852225A
- Authority
- JP
- Japan
- Prior art keywords
- fts
- day
- page
- eae
- multiple sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010003422 Circulating Thymic Factor Proteins 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 22
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 7
- 206010061598 Immunodeficiency Diseases 0.000 claims description 5
- 230000007813 immunodeficiency Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 21
- 241000700199 Cavia porcellus Species 0.000 abstract description 12
- 206010029240 Neuritis Diseases 0.000 abstract description 6
- 210000002966 serum Anatomy 0.000 abstract description 5
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 208000016192 Demyelinating disease Diseases 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- 238000010255 intramuscular injection Methods 0.000 abstract description 2
- 239000007927 intramuscular injection Substances 0.000 abstract description 2
- 238000010253 intravenous injection Methods 0.000 abstract description 2
- 201000002491 encephalomyelitis Diseases 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- 241000282693 Cercopithecidae Species 0.000 description 40
- 208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 21
- 206010033799 Paralysis Diseases 0.000 description 19
- 241000700198 Cavia Species 0.000 description 18
- 230000003053 immunization Effects 0.000 description 18
- 238000002649 immunization Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 238000011282 treatment Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 206010003591 Ataxia Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 235000019789 appetite Nutrition 0.000 description 6
- 230000036528 appetite Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 206010047571 Visual impairment Diseases 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000029257 vision disease Diseases 0.000 description 5
- 230000004393 visual impairment Effects 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 230000002747 voluntary effect Effects 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 3
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- YNKFCNRZZPFMEX-XHPDKPNGSA-N desmopressin acetate trihydrate Chemical compound O.O.O.CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 YNKFCNRZZPFMEX-XHPDKPNGSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229940028441 minirin Drugs 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 108010046075 Thymosin Proteins 0.000 description 2
- 102000007501 Thymosin Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 239000000724 thymus hormone Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000037187 Autoimmune Experimental Neuritis Diseases 0.000 description 1
- 101100129922 Caenorhabditis elegans pig-1 gene Proteins 0.000 description 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101100520057 Drosophila melanogaster Pig1 gene Proteins 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000013178 decreased motor response Diseases 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000029436 dilated pupil Diseases 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 235000008212 improved nutritional status Nutrition 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- PQFRTXSWDXZRRS-UHFFFAOYSA-N ronidazole Chemical compound CN1C(COC(N)=O)=NC=C1[N+]([O-])=O PQFRTXSWDXZRRS-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 108700016958 thymosin fraction 5 Proteins 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56148725A JPS5852225A (ja) | 1981-09-22 | 1981-09-22 | 脱髄疾患治療剤 |
| DE19823234947 DE3234947A1 (de) | 1981-09-22 | 1982-09-21 | Arzneimittel zur behandlung von immundefektzustaenden |
| GB08227075A GB2109684B (en) | 1981-09-22 | 1982-09-22 | Serum thymic factor for use in the treatment of immuno deficiency |
| FR8215984A FR2513125B1 (fr) | 1981-09-22 | 1982-09-22 | Medicament curatif du deficit immunitaire |
| US06/734,259 US5112810A (en) | 1981-09-22 | 1985-05-15 | Method for treating multiple sclerosis |
| US07/498,637 US5464816A (en) | 1981-09-22 | 1990-03-26 | Method and pharmaceutical compositions for treating immunodeficiencies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56148725A JPS5852225A (ja) | 1981-09-22 | 1981-09-22 | 脱髄疾患治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5852225A true JPS5852225A (ja) | 1983-03-28 |
| JPH0371413B2 JPH0371413B2 (enExample) | 1991-11-13 |
Family
ID=15459209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56148725A Granted JPS5852225A (ja) | 1981-09-22 | 1981-09-22 | 脱髄疾患治療剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US5112810A (enExample) |
| JP (1) | JPS5852225A (enExample) |
| DE (1) | DE3234947A1 (enExample) |
| FR (1) | FR2513125B1 (enExample) |
| GB (1) | GB2109684B (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01250325A (ja) * | 1987-12-25 | 1989-10-05 | Mitsui Toatsu Chem Inc | 膵疾患等の予防・治療剤 |
| JPH01316328A (ja) * | 1988-06-15 | 1989-12-21 | Mitsui Toatsu Chem Inc | 老化防止、細胞賦活、老人病予防・治療のための薬剤 |
| US5288706A (en) * | 1987-12-25 | 1994-02-22 | Mitsui Toatsu Chemicals, Incorporated | Medicament for prevention and remedy of diseases of the pancreas and others |
| US5352665A (en) * | 1987-11-24 | 1994-10-04 | Mitsui Toatsu Chemicals, Incorporated | Method of treating disease caused by the infection of virus |
| JP2004203855A (ja) * | 2002-06-24 | 2004-07-22 | Akira Awaya | アレルギー性鼻炎・結膜炎あるいは皮膚アレルギーやアトピー性皮膚炎の予防・治療法 |
| JP2010507650A (ja) * | 2006-10-27 | 2010-03-11 | シグマ − タウ インデュストリエ ファーマシューティッツェ リウニーテ ソシエタ ペル アチオニ | 自己免疫疾患の予防及び治療用の薬剤を調製するためのチモシンアルファ１の使用 |
| JP2011518212A (ja) * | 2008-04-21 | 2011-06-23 | セーエルエル ファルマ | 自己免疫疾患の治療における、ｐａｔノナペプチドの使用 |
| JP2012522005A (ja) * | 2009-03-26 | 2012-09-20 | ヘンリー フォード ヘルス システム | 神経損傷および神経変性疾患後の神経学的転帰を改善する方法 |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150136A (en) * | 1995-11-14 | 2000-11-21 | The Regents Of The University Of California | Nucleotide sequence encoding oligodendrocyte-specific protein |
| US5756300A (en) * | 1995-11-14 | 1998-05-26 | Research Genetics, Inc. | Oligodendrocyte-specific protein and method for diagnosing and treating disease |
| FR2741076B1 (fr) * | 1995-11-15 | 1998-01-30 | Rech De Pathologie Appliquee S | Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant |
| US6103748A (en) * | 1998-06-19 | 2000-08-15 | Bryan; Thomas B. | Method of treating an autoimmune disorder |
| AU2001280199A1 (en) * | 2000-08-28 | 2002-03-13 | Akira Awaya | Medicinal compositions |
| US6716434B1 (en) * | 2000-09-19 | 2004-04-06 | Daniel R. Ansley | Composition and method for immunostimulation in non- mammalian vertebrates |
| US6719984B1 (en) * | 2000-09-19 | 2004-04-13 | Daniel R. Ansley | Composition and method for immunomodulation in mammals |
| US7858602B2 (en) * | 2000-10-16 | 2010-12-28 | Rodriguez Victorio C | Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| FR2830451B1 (fr) * | 2001-10-09 | 2004-04-30 | Inst Nat Sante Rech Med | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
| US7695713B2 (en) * | 2002-08-08 | 2010-04-13 | Baylor College Of Medicine | Isolation and identification of T cells |
| PT2016414E (pt) * | 2006-05-05 | 2015-11-24 | Opexa Therapeutics | Vacina de células t |
| RU2010146489A (ru) | 2008-04-16 | 2012-05-27 | Момента Фармасьютикалз, Инк. (Us) | Анализ композиций сополимера аминокислот |
| US9468662B2 (en) | 2010-07-12 | 2016-10-18 | Orphit | Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases |
| FR2962335B1 (fr) * | 2010-07-12 | 2013-01-18 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives |
| WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
| US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| US11382885B2 (en) | 2017-06-07 | 2022-07-12 | The Regents Of The University Of California | Compositions for treating fungal and bacterial biofilms and methods of using the same |
| US12226386B2 (en) | 2018-12-03 | 2025-02-18 | The Regents Of The University Of California | Compositions and methods for treating biofilms |
| US12109176B1 (en) | 2023-04-20 | 2024-10-08 | Thomas Bryan | Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7502830A (nl) * | 1974-03-25 | 1975-09-29 | Jean Francois Bach En Dr Jean | Werkwijze voor het isoleren van een polypeptide hormoon. |
| DE2732587A1 (de) * | 1976-09-22 | 1978-03-23 | Bach Jean Francois | Polypeptid mit thymischer wirksamkeit |
| FR2365347A2 (fr) * | 1976-09-22 | 1978-04-21 | Bach Jean Francois | Nouvelle hormone polypeptide possedant une activite thymique et son procede de preparation |
| CH637111A5 (fr) * | 1977-05-25 | 1983-07-15 | Anvar | Composes polypeptidiques a activite thymique ou antagoniste et leurs procedes de synthese. |
| JPS54148722A (en) * | 1978-05-12 | 1979-11-21 | Takeda Chem Ind Ltd | Nonapeptide and its preparation |
| JPS5839144B2 (ja) * | 1978-05-15 | 1983-08-27 | 株式会社トクヤマ | 炭酸モノエステルの製造方法 |
| JPS56148725A (en) * | 1980-04-18 | 1981-11-18 | Fujitsu Ltd | Magnetic head |
-
1981
- 1981-09-22 JP JP56148725A patent/JPS5852225A/ja active Granted
-
1982
- 1982-09-21 DE DE19823234947 patent/DE3234947A1/de not_active Ceased
- 1982-09-22 GB GB08227075A patent/GB2109684B/en not_active Expired
- 1982-09-22 FR FR8215984A patent/FR2513125B1/fr not_active Expired
-
1985
- 1985-05-15 US US06/734,259 patent/US5112810A/en not_active Expired - Fee Related
-
1990
- 1990-03-26 US US07/498,637 patent/US5464816A/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352665A (en) * | 1987-11-24 | 1994-10-04 | Mitsui Toatsu Chemicals, Incorporated | Method of treating disease caused by the infection of virus |
| JPH01250325A (ja) * | 1987-12-25 | 1989-10-05 | Mitsui Toatsu Chem Inc | 膵疾患等の予防・治療剤 |
| US5288706A (en) * | 1987-12-25 | 1994-02-22 | Mitsui Toatsu Chemicals, Incorporated | Medicament for prevention and remedy of diseases of the pancreas and others |
| JPH01316328A (ja) * | 1988-06-15 | 1989-12-21 | Mitsui Toatsu Chem Inc | 老化防止、細胞賦活、老人病予防・治療のための薬剤 |
| JP2004203855A (ja) * | 2002-06-24 | 2004-07-22 | Akira Awaya | アレルギー性鼻炎・結膜炎あるいは皮膚アレルギーやアトピー性皮膚炎の予防・治療法 |
| JP2010507650A (ja) * | 2006-10-27 | 2010-03-11 | シグマ − タウ インデュストリエ ファーマシューティッツェ リウニーテ ソシエタ ペル アチオニ | 自己免疫疾患の予防及び治療用の薬剤を調製するためのチモシンアルファ１の使用 |
| JP2011518212A (ja) * | 2008-04-21 | 2011-06-23 | セーエルエル ファルマ | 自己免疫疾患の治療における、ｐａｔノナペプチドの使用 |
| JP2012522005A (ja) * | 2009-03-26 | 2012-09-20 | ヘンリー フォード ヘルス システム | 神経損傷および神経変性疾患後の神経学的転帰を改善する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2109684A (en) | 1983-06-08 |
| US5112810A (en) | 1992-05-12 |
| GB2109684B (en) | 1986-05-29 |
| FR2513125A1 (fr) | 1983-03-25 |
| JPH0371413B2 (enExample) | 1991-11-13 |
| DE3234947A1 (de) | 1983-04-07 |
| US5464816A (en) | 1995-11-07 |
| FR2513125B1 (fr) | 1987-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5852225A (ja) | 脱髄疾患治療剤 | |
| Borel et al. | Effects of the new anti-lymphocytic peptide cyclosporin A in animals | |
| EP1012188B1 (de) | Zusammensetzung zur therapie von diabetes mellitus und fettsucht | |
| DE69127470T2 (de) | Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen | |
| JP2004525180A (ja) | 炎症の治療に有用な脂肪族アルコール及び脂肪酸エステル | |
| KR20120104422A (ko) | 중추신경계 (ｃｎｓ) 자가면역 탈수초 질환의 치료 또는 예방을 위한 디아족사이드 | |
| WO2007131218A2 (en) | Compositions and methods for modulating the immune system | |
| CA2222770A1 (en) | Method of treating rheumatoid arthritis with low dose type ii collagen | |
| DE69610295T3 (de) | Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen. | |
| KR0159046B1 (ko) | 포유류의 자기면역 포도막망막염의 치료 또는 예방방법 | |
| JPH10500109A (ja) | 多発性硬化症のための組成物および治療方法 | |
| KR100333148B1 (ko) | 당뇨질환예방제및치료제로서사용되는Vα14Jα281을함유하는가용성T-세포수용체α쇄및유도체 | |
| RU2196606C2 (ru) | Применение белков в качестве агентов против аутоиммунных заболеваний | |
| US6790447B1 (en) | Peptides for treatment of autoimmune diseases | |
| St Georgiev | Immunomodulatory activity of small peptides | |
| Efendić et al. | Effect of somatostatin on basal and glucose induced insulin release in five patients with hyperinsulinaemia | |
| JP2007527851A (ja) | 乾癬の治療薬を製造するためのカハラリド化合物の使用 | |
| KR102292147B1 (ko) | 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트 | |
| CN111803487B (zh) | 银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途 | |
| Bastos et al. | Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones. | |
| WO1997003686A1 (en) | Tnf receptor and steroid hormone in a combined therapy | |
| KR100719020B1 (ko) | 재조합 아세틸콜린 수용체 폴리펩티드, 폴리펩티드 유도체및 이를 유효성분으로 포함하는 중증근무력증 치료제 | |
| US20030007964A1 (en) | Method for treating rheumatoid arthritis with composition containing histone | |
| WO2020207398A1 (zh) | 银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途 | |
| JP2558147B2 (ja) | 免疫性疾患治療剤 |